Table 5.
Baseline characteristics of patients not on AC by cohort
| Variable | Cohort 2 (n=375) |
Cohort 3 (n=356) |
Cohort 4 (n=229) |
Cohort 5 (n=235) |
Total C2 to C5 (n=1195) |
| Women, n (%) | 166 (44.3) | 140 (39.3) | 89 (38.9) | 97 (41.3) | 492 (41.2) |
| Age at diagnosis, years, mean (SD) | 75.2 (9.8) | 74.0 (9.9) | 73.8 (10.7) | 74.9 (9.9) | 74.5 (10.0) |
| Age at diagnosis, years, median (IQR) | 77.0 (69.0 to 82.0) | 75.0 (69.0 to 81.0) | 74.0 (68.0 to 81.0) | 75.0 (69.0 to 82.0) | 75.0 (69.0 to 82.0) |
| Age group, n (%) | |||||
| <65 | 51 (13.6) | 60 (16.9) | 38 (16.6) | 32 (13.6) | 181 (15.1) |
| 65–74 | 102 (27.2) | 114 (32.0) | 78 (34.1) | 76 (32.3) | 370 (31.0) |
| ≥75 | 222 (59.2) | 182 (51.1) | 113 (49.3) | 127 (54.0) | 644 (53.9) |
| Care setting at diagnosis, n (%) | |||||
| Internal medicine | 66 (17.6) | 73 (20.5) | 49 (21.4) | 37 (15.7) | 255 (18.8) |
| Cardiology | 54 (14.4) | 53 (14.9) | 30 (13.1) | 29 (12.3) | 166 (13.9) |
| Neurology | – | – | 1 (0.4) | 1 (0.4) | 2 (0.2) |
| Geriatrics | 7 (1.9) | 8 (2.2) | 3 (1.3) | 4 (1.7) | 22 (1.8) |
| Primary care/general practice | 248 (66.1) | 222 (62.4) | 146 (63.3) | 164 (69.8) | 780 (65.3) |
| Medical history, n (%) | |||||
| Congestive heart failure | 25 (6.7) | 18 (5.1) | 10 (4.4) | 15 (6.4) | 68 (5.7) |
| History of hypertension | 269 (71.7) | 245 (68.8) | 135 (59.2) | 141 (60.3) | 790 (66.2) |
| Diabetes mellitus | 46 (12.3) | 50 (14.0) | 29 (12.7) | 31 (13.2) | 156 (13.1) |
| Stroke | 23 (6.1) | 20 (5.6) | 7 (3.1) | 17 (7.2) | 67 (5.6) |
| Systemic embolism | 2 (0.5) | 2 (0.6) | – | 1 (0.4) | 5 (0.4) |
| Coronary artery disease | 80 (21.3) | 57 (16.0) | 44 (19.2) | 43 (18.3) | 224 (18.7) |
| Vascular disease | 46 (12.3) | 34 (9.6)a | 31 (13.5) | 32 (13.7)b | 143 (12.0)c |
| History of bleeding | 23 (6.1) | 19 (5.4) | 13 (5.7) | 14 (6.0) | 69 (5.8) |
| Moderate to severe CKD* | 108 (28.8) | 82 (23.0) | 47 (20.5) | 65 (27.7) | 302 (25.3) |
| Risk scores | |||||
| CHA2DS2-VASc, mean (SD) | 3.2 (1.5)d | 3.0 (1.4)e | 3.0 (1.5)f | 3.2 (1.5)g | 3.1 (1.5)h |
| CHA2DS2-VASc, median (IQR) | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 4.0) |
| CHA2DS2-VASc, 0–1, n (%) | 41 (11.6) | 46 (13.8) | 34 (16.5) | 27 (13.4) | 148 (13.5) |
| HAS-BLED, mean (SD) | 2.2 (0.9)i | 2.1 (0.9)j | 1.7 (1.0)k | 1.9 (1.1)l | 2.0 (1.0)m |
| HAS-BLED, median (IQR) | 2.0 (2.0 to 3.0) | 2.0 (2.0 to 3.0) | 2.0 (1.0 to 2.0) | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) |
| HAS-BLED, 0–2, n (%) | 164 (66.6) | 173 (71.1) | 122 (77.7) | 96 (71.6) | 555 (71.2) |
Patients missing: a1, b1, c2, d22, e24, f22, g34, h102, i129, j113, k72, l101, m415.
*Includes NKF KDOQI stages III–V.
AC, anticoagulant; CHA2DS2-VASc, cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)–vascular disease, age 65–74 and sex category (female); CKD, chronic kidney disease; HAS-BLED, hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, elderly (>65), drugs/alcohol concomitantly (1 point each), NKF KDOQI, National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative.